Blood Sugar Makes You High
Johnson & Johnson has been honored for its dedication to people, innovation and the health of people around the world! Therefore, A Model Company.
Economically, a new blockbuster is emerging! The company has received a takeover bid for its blood glucose control business. The investment company Platinum Equity is willing to pay 2.1 billion US-Dollar for this division of the US pharmaceutical company.
Our recognition - blood sugar makes you high!
What has happened lately?
Johnson & Johnson hit the list of the best jobs Glassdoor's 2018. The company was named to Glassdoor’s 2018 List of best places to work, based solely on the positive feedback from its employees.
Additionally, Johnson & Johnson named a 2017 Fortune's Most Admired Company.
However, last year's financial results were rather disappointing. Johnson & Johnson's net income for 2017 was $1.3 billion, compared to $16.5 billion a year earlier.
A contributing cause for the lousy results was the tax payments of $13.6 billion required in the fourth quarter of last year.
At the same time, the company's worldwide sales for the full-year 2017 grew. According to Johnson & Johnson's 2017 Full Year Earnings Report, the company announced $76.5 billion in sales in 2017, with growth reported in all three sectors: Consumer, Medical Devices and Pharmaceuticals. This is an increase of 6.3% versus 2016.
What to expect from Johnson&Johnson this year?
In the annual forecast for 2018, the company indicated the expected revenue of $80.6 billion to $81.4 billion. The company also announced adjusted earnings guidance for full-year 2018 of $8.00 to $8.20 per share compared to recorded $7.30 in 2017.
Afterwards, as mentioned earlier, there is a lucrative takeover bid of $2.1 billion for its blood glucose control business.
What do the technical analysis methods I use say?
Oscillator: The RSI is around 53 - the rise above the 50 mark is reached!
Price Indicator: The stock price is below the SMA200 ($136). This resistance is now to crack!
Trend indicator: The MACD is currently in the positive zone.
As it is seen in the chart, after the publication of the financial figures at the beginning of the year, there was a veritable consolidation. This could have currently found a bottom.
The question arises: "Is a stable countermovement started now?"
Now the SMA 200 (blue line at around $136) has to be overcome, after this the way to the first target (visible in the chart as a green line) is probably largely free.
The risk management tool used here is the own-developed “Traffic Signals System” (TSS) and is preferably used in analyzes by Ritschy Dobetsberger.
The black line in the chart: the starting price of the idea is 133.80 US-Dollar.
The red line in the chart: the stop loss is lying at 125.00 US-Dollar.
The green line in the chart: First goal in the idea at around 148 US-Dollar.
Disclosure:
"The trading ideas published here are neither to be understood as a recommendation nor as an offer or an invitation to buy or sell financial instruments and should not be understood as such.
You must also assume that the author holds the recommended position in his portfolio and benefits from the implementation of his trading ideas."
Economically, a new blockbuster is emerging! The company has received a takeover bid for its blood glucose control business. The investment company Platinum Equity is willing to pay 2.1 billion US-Dollar for this division of the US pharmaceutical company.
Our recognition - blood sugar makes you high!
What has happened lately?
Johnson & Johnson hit the list of the best jobs Glassdoor's 2018. The company was named to Glassdoor’s 2018 List of best places to work, based solely on the positive feedback from its employees.
Additionally, Johnson & Johnson named a 2017 Fortune's Most Admired Company.
However, last year's financial results were rather disappointing. Johnson & Johnson's net income for 2017 was $1.3 billion, compared to $16.5 billion a year earlier.
A contributing cause for the lousy results was the tax payments of $13.6 billion required in the fourth quarter of last year.
At the same time, the company's worldwide sales for the full-year 2017 grew. According to Johnson & Johnson's 2017 Full Year Earnings Report, the company announced $76.5 billion in sales in 2017, with growth reported in all three sectors: Consumer, Medical Devices and Pharmaceuticals. This is an increase of 6.3% versus 2016.
What to expect from Johnson&Johnson this year?
In the annual forecast for 2018, the company indicated the expected revenue of $80.6 billion to $81.4 billion. The company also announced adjusted earnings guidance for full-year 2018 of $8.00 to $8.20 per share compared to recorded $7.30 in 2017.
Afterwards, as mentioned earlier, there is a lucrative takeover bid of $2.1 billion for its blood glucose control business.
What do the technical analysis methods I use say?
Oscillator: The RSI is around 53 - the rise above the 50 mark is reached!
Price Indicator: The stock price is below the SMA200 ($136). This resistance is now to crack!
Trend indicator: The MACD is currently in the positive zone.
As it is seen in the chart, after the publication of the financial figures at the beginning of the year, there was a veritable consolidation. This could have currently found a bottom.
The question arises: "Is a stable countermovement started now?"
Now the SMA 200 (blue line at around $136) has to be overcome, after this the way to the first target (visible in the chart as a green line) is probably largely free.
The risk management tool used here is the own-developed “Traffic Signals System” (TSS) and is preferably used in analyzes by Ritschy Dobetsberger.
The black line in the chart: the starting price of the idea is 133.80 US-Dollar.
The red line in the chart: the stop loss is lying at 125.00 US-Dollar.
The green line in the chart: First goal in the idea at around 148 US-Dollar.
Disclosure:
"The trading ideas published here are neither to be understood as a recommendation nor as an offer or an invitation to buy or sell financial instruments and should not be understood as such.
You must also assume that the author holds the recommended position in his portfolio and benefits from the implementation of his trading ideas."
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.